CN104974222B - Conjugated peptide compounds as protein tyrosine kinase inhibitors - Google Patents
Conjugated peptide compounds as protein tyrosine kinase inhibitors Download PDFInfo
- Publication number
- CN104974222B CN104974222B CN201510322699.8A CN201510322699A CN104974222B CN 104974222 B CN104974222 B CN 104974222B CN 201510322699 A CN201510322699 A CN 201510322699A CN 104974222 B CN104974222 B CN 104974222B
- Authority
- CN
- China
- Prior art keywords
- compound
- protein tyrosine
- tyrosine kinase
- formula
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 7
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 11
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract description 6
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001151 peptidyl group Chemical group 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108060006633 protein kinase Proteins 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- -1 heteroaryl aryl ureas Chemical class 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a compound of formula (I) as a protein tyrosine kinase inhibitor, which is a coupling peptide compound; the compounds can be used to treat one or more protein tyrosine kinase mediated diseases.
Description
Technical Field
The invention belongs to the field of chemistry, and particularly relates to an anticancer compound.
Background
Protein Kinases (PKs) are enzymes that catalyze the phosphorylation of specific serine, threonine or tyrosine residues in cellular proteins. Post-translational modification of these substrate proteins serves as a molecular switch that regulates cell proliferation, activation and/or differentiation. Abnormal or excessive PK activity has been observed in a number of disease states including benign and malignant proliferative disorders. In many cases, in vitro treatment of diseases such as proliferative diseases using PK inhibitors has been feasible, and in many cases, in vivo treatment of diseases such as proliferative diseases using PK inhibitors has been feasible. The kinases are largely divided into two groups, those that specifically phosphorylate serine and threonine and those that specifically phosphorylate tyrosine. In addition, some kinases, called "dual specificity" kinases, are capable of phosphorylating tyrosine as well as serine/threonine residues.
WO2006/000420 (pages 1-8 in particular) discloses details regarding PKs, their mode of action and their relationship to the condition or disorder to be treated. The document also discloses heteroaryl aryl ureas useful in the treatment of protein kinase dependent diseases. Furthermore, W003/023004 and W002/102972 disclose disorders arising from FGFR3 mutations. Furthermore, W005/118580 generically discloses quinoline derivatives useful as HIV inhibitors. In these documents and the references cited therein relating to protein kinases, it is reasonable to expect that modulation of aberrant activity, in particular inhibition of the kinase activity, is useful for the diseases mentioned in the literature.
Although the molecules disclosed in the above references are believed to be active, they still have some disadvantages. Thus, there remains an unmet need for improved (e.g., highly affinity and/or selective) molecules that block aberrant constitutive receptor protein tyrosine kinase activity, particularly FGFR activity, and thereby address the clinical manifestations associated with the above mutations and modulate various biological functions. In view of the large number of protein kinase inhibitors, as well as numerous proliferative diseases and other PK related diseases, there is a continuing need to provide novel compounds useful as PK inhibitors and thus for the treatment of said Protein Tyrosine Kinase (PTK) related diseases.
Disclosure of Invention
The invention aims to provide a peptide chain substituted compound with low toxicity and good anticancer effect aiming at the defects of the prior art.
The present invention is based on certain small molecule compounds that interact with protein tyrosine kinases by introducing a peptide (amino acid) chain into the parent backbone to provide peptidyl substituted compounds that interact with protein tyrosine kinases.
The technical purpose of the invention is realized by the following technical scheme:
A peptidyl substituted compound has a structural formula shown in formula I,
r1 is tripeptide or tetrapeptide.
The amino acid sequence of R1 is GTH, GAK, GKR, GKD, GRQ, GAS, GLA, GEKL, GMAW, GSEH, GRKG. Wherein each capital letter represents an amino acid well known in the art.
Still further provided is a method for preparing the above peptidyl substituted compound, comprising the steps of:
(1) reacting [5- [ [ (2, 4, 6-trimethylphenyl) amino group]Carbonyl radical]-4-methyl-2-thiazolyl]Carbamic acid, 1, 1-dimethylethyl ester (10g, 26.63mmol) in trifluoroacetic acid (100mL)The solution was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure and the residue was diluted with ethyl acetate (700 mL) and with 5% KHCO3Aqueous solution (400mL, 2 ×), water and brine wash; drying (MgSO)4) Filtered and concentrated. The residue was washed with diethyl ether (200mL) and acetonitrile (100mL) to give compound S1 as a white solid;
(2) performing a alkylation reaction on S1 and chloroacetic acid in an alkaline environment, and performing a chlorination reaction on the obtained product and thionyl chloride to obtain a compound S2 or realize Cl substitution by adopting other methods commonly used in the field;
(3) carrying out substitution reaction on S2 and glycine to obtain a compound S3;
(4) and respectively connecting the compound of S3 and different amino acids protected by Fmoc groups to Rink AmideAM resin to perform condensation reaction to obtain the target compound (shown as formula I). The condensation reaction is carried out by a polypeptide solid phase synthesis method, and then trifluoroacetic acid is used for removing resin, so as to finally obtain the peptidyl substituted compound.
Further provides the application of the peptidyl substituted compound in the preparation of anti-cancer drugs.
The dosage form of the anticancer drug is tablets, pills, capsules, injections, suspending agents or emulsions.
Compared with the prior art, the invention has the following beneficial effects:
1. the novel peptidyl substituted compound protein tyrosine kinase inhibits and shows good inhibitory activity to cancer cells, thereby having remarkable inhibitory action to various cancer cell strains;
2. the novel peptidyl substituted compound has low toxicity to normal cells and high safety in the application of preparing anticancer drugs;
3. the novel peptidyl substituted compound can be prepared into various dosage forms of anti-cancer drugs, and has high medical value and wide market prospect.
Detailed Description
EXAMPLE 1 preparation of peptidyl substituted Compounds
(1) Reacting [5- [ [ (2, 4, 6-trimethylphenyl) amino group]Carbonyl radical]-4-methyl-2-thiazolyl]A solution of carbamic acid, 1, 1-dimethylethyl ester (10g, 26.63mmol) in trifluoroacetic acid (100mL) was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure and the residue was diluted with ethyl acetate (700 mL) and with 5% KHCO3Aqueous solution (400mL, 2 ×), water and brine wash; drying (MgSO)4) Filtered and concentrated. The residue was washed with diethyl ether (200mL) and acetonitrile (100mL) to give compound S1 as a white solid;
(2) performing a alkylation reaction on S1 and chloroacetic acid in an alkaline environment, and performing a chlorination reaction on the obtained product and thionyl chloride to obtain a compound S2 or realize Cl substitution by adopting other methods commonly used in the field;
(3) carrying out substitution reaction on S2 and glycine to obtain a compound S3;
(4) the compound of S3 was linked to Rink Amide AM resin with different amino acids (GTH, GAK, GKR, GKD, GRQ, GAS, GLA, GEKL, GMAW, GSEH, GRKG) protected with Fmoc group, respectively, and then subjected to condensation reaction to obtain the objective compound. The condensation reaction is carried out by a polypeptide solid phase synthesis method, and then trifluoroacetic acid is used for removing resin, so as to finally obtain the peptidyl substituted compound. Through tandem liquid quality identification, the compound structure is correct.
Example 2 functional validation of peptidyl substituted Compounds
Human lung adenocarcinoma cell line A549 was cultured in RPMI1640 medium (containing 10% inactivated calf serum, 100U/mL penicillin and 100U/mL streptomycin) and grown in A5% CO2 incubator at 37 ℃.
Cell suspension was prepared at 1X 105/mL by digestion, and 100. mu.L of cell suspension was added to each well in a 96-well plate and cultured for 24 h for adherence. Changing the solution, adding culture solution containing drugs with different concentrations, each well is 100 μ L, each concentration is provided with 4 parallel wells, and the final concentration of the compound is 2.0 mg/L. The culture was continued for 72 h. mu.L of MTT (5 mg/mL) was added to each well and returned to the incubator for further incubation for 4 h. Discard the supernatant, add 150. mu.L DMSO into each well, shake slightly for 15 min to dissolve the crystal completely, adjust the blank control well to zero, select 490 nm wavelength within 20 min, and measure the absorbance value (A) of each well on an automatic fluorescence microplate reader. The experiment was repeated 3 times and the average was taken. Calculating the inhibition rate of cell proliferation: inhibition% = (1-experimental group a value/control group a value) × 100%. The inhibition results were as follows:
| class of compounds | Human lung adenocarcinoma cell strain A549 inhibition rate% | Inhibition rate of normal human epidermal cells% |
| Compound S1 | 30% | 20.8% |
| Substituted by the formula I-GTH | 90.2% | 1.2% |
| Substituted by the formula I-GAK | 91.3% | 2.1% |
| A substitution of the formula I-GKR | 92.5% | 1.7% |
| Substituted by the formula I-GKD | 89.7% | 1.5% |
| Substituted of formula I-GRQ | 89.1% | 1.1% |
| Substitution of formula I-GAS | 90.2% | 1.8% |
| Substituted by formula I-GLA | 91.5% | 2.0% |
| Substitution of formula I-GEKL | 88.3% | 2.3% |
| Substituted by the formula I-GMAW | 92.4% | 1.4% |
| Substitution of formula I-GSEH | 93.5% | 1.8% |
| Substituted by the formula I-GRKG | 90.1% | 1.7% |
The compound has obvious inhibition effect on cancer cells when the concentration is 2 mg/L. The function characteristics and the structure-activity relationship of the compounds can be well illustrated. Therefore, the peptidyl substituted compound can be used for preparing an anticancer drug taking kinase as a target.
Meanwhile, MCF-7 cells are adopted for testing, and basically consistent test results are obtained. Indicating that the compound has broad-spectrum anticancer effect.
Claims (3)
1. A compound is characterized in that the structural formula is shown as a formula I,
and R1 is GTH, GAK, GKR, GKD, GRQ, GAS, GLA, GEKL, GMAW, GSEH or GRKG.
2. The use of a compound according to claim 1 in the preparation of an anti-cancer medicament, wherein said anti-cancer medicament is an anti-lung or breast cancer medicament.
3. The use of the compound of claim 1 in the preparation of an anticancer agent in the form of a tablet, pill, capsule, injection, suspension or emulsion, wherein the anticancer agent is an anti-lung cancer or breast cancer agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510322699.8A CN104974222B (en) | 2015-06-14 | 2015-06-14 | Conjugated peptide compounds as protein tyrosine kinase inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510322699.8A CN104974222B (en) | 2015-06-14 | 2015-06-14 | Conjugated peptide compounds as protein tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104974222A CN104974222A (en) | 2015-10-14 |
| CN104974222B true CN104974222B (en) | 2020-06-02 |
Family
ID=54271226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510322699.8A Active CN104974222B (en) | 2015-06-14 | 2015-06-14 | Conjugated peptide compounds as protein tyrosine kinase inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104974222B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144910A0 (en) * | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
-
2015
- 2015-06-14 CN CN201510322699.8A patent/CN104974222B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104974222A (en) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Méndez et al. | Discovery of potent and selective inhibitors of the Escherichia coli M1-aminopeptidase via multicomponent solid-phase synthesis of tetrazole-peptidomimetics | |
| Naik et al. | 3, 4-Dihydropyrimidinone-coumarin analogues as a new class of selective agent against S. aureus: Synthesis, biological evaluation and molecular modelling study | |
| EA021838B1 (en) | 2,5-piperazinedione derivatives as apaf-1 inhibitors | |
| US20160024130A1 (en) | Semi-synthetic mithramycin derivatives with anti-cancer activity | |
| DE69924292T2 (en) | PYRAZOL COMPOUNDS AND ITS USE | |
| JP2021504314A (en) | MYST family histone acetyltransferase inhibitor | |
| CN113599504B (en) | Carrier-free protein intracellular delivery prodrug, and preparation method and application thereof | |
| US9309286B2 (en) | Compositions and methods for augmenting permeability barriers | |
| Yu et al. | Study on glyco-modification of endostatin-derived synthetic peptide endostatin2 (ES2) by soluble chitooligosaccharide | |
| CN104974222B (en) | Conjugated peptide compounds as protein tyrosine kinase inhibitors | |
| WO2012165356A1 (en) | Thermosensitive polyamino acid or salt thereof | |
| CN110551102B (en) | ALK covalent inhibitor and use thereof | |
| Chowdary et al. | A short hydrophobic peptide conjugated 3, 5-disubstituted pyrazoles as antibacterial agents with DNA gyrase inhibition | |
| CN105418733A (en) | Preparation and application of conjugate of cell penetrating polypeptide and antitumor drug | |
| CN104774245A (en) | Preparation method and use of brain targeting peptide-antineoplastic drug conjugate | |
| CN108676009A (en) | Pyrimidine derivatives as HER2 tyrosine kinase inhibitors and its application | |
| CN105315348A (en) | Transmembrane polypeptide, preparation method and application thereof | |
| EP3189064B1 (en) | Platinum (iv) complex with increased antitumor efficacy | |
| CN103724251B (en) | STAT3 (Signal Transducer and Activator of Transcription 3)-targeting small molecular compound as well as preparation method and application thereof | |
| CN108689946B (en) | 2-substituted sulfenyl acetamide compound and preparation method and application thereof | |
| CN102532192B (en) | Acetaminophen-cyclophosphamide anti-tumor drug and preparation method thereof | |
| CN103910734B (en) | A kind of DPP-4 inhibitor with piperazine structure | |
| US11607457B2 (en) | Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same | |
| CN108239081A (en) | A kind of compound for inhibiting ROCK and its application | |
| CN118164960A (en) | Targeted p53 acetylation difunctional small molecule, preparation method and application thereof, and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Yang Inventor after: Fang Qiaohui Inventor after: Gao Hua Inventor after: Zhang Wenle Inventor before: Yang Yang |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200508 Address after: Room 2 407, Shenzhen biological incubation base, No. 10, Gaoxin Middle Road, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province Applicant after: SHENZHEN CURE & SURE BIOTECH Ltd. Address before: 100711, No. 46 West Fourth Street, Beijing, Dongcheng District Applicant before: Yang Yang |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |